A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck

John L. Eckenrode, Richard H. Wheeler, Arlene A. Forastiere

Research output: Contribution to journalArticlepeer-review

Abstract

Sixteen patients with advanced squamous cell carcinoma of the head and neck were entered into a phase II trial of Aclacinomycin-A (ACM), 100 mg/M2 administered by brief infusion every three weeks. All patients had received prior radiation therapy and prior non-anthracycline containing chemotherapy. No clinically significant disease regression was observed in fourteen patients having adequate trials. The major toxicity was myelosuppression; leukopenia occurred in 93% of patients. Gastro-intestinal toxicity was mild and included two patients with transient liver function test abnormalities. No antitumor activity was observed in this patient population which was heavily pre-treated and had a median Karnofsky performance status of only 60%. The results of other phase II trials of ACM-A have been similarly disappointing suggesting that it is not a clinically useful agent in the treatment of solid tumors.

Original languageEnglish (US)
Pages (from-to)389-392
Number of pages4
JournalInvestigational New Drugs
Volume3
Issue number4
DOIs
StatePublished - Dec 1985
Externally publishedYes

Keywords

  • Aclacinomycin-A
  • Aclarubicin
  • Head and Neck Cancer
  • Phase II trial

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'A phase II trial of aclacinomycin-A in advanced squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this